Last reviewed · How we verify
progenipoietin
progenipoietin is a Biologic drug developed by University of Southern California. It is currently in discontinued development.
At a glance
| Generic name | progenipoietin |
|---|---|
| Sponsor | University of Southern California |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- progenipoietin CI brief — competitive landscape report
- progenipoietin updates RSS · CI watch RSS
- University of Southern California portfolio CI
Frequently asked questions about progenipoietin
What is progenipoietin?
progenipoietin is a Biologic drug developed by University of Southern California.
Who makes progenipoietin?
progenipoietin is developed by University of Southern California (see full University of Southern California pipeline at /company/university-of-southern-california).
What development phase is progenipoietin in?
progenipoietin is in discontinued.
Related
- Manufacturer: University of Southern California — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing